Comparison of 48-Week Efficacies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimens: A Systematic Review and Network Meta-Analysis - Sorbonne Université
Journal Articles HIV medicine Year : 2018

Comparison of 48-Week Efficacies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimens: A Systematic Review and Network Meta-Analysis

Domains

Life Sciences [q-bio]
Fichier principal
Vignette du fichier
hal-03703931.pdf (463.48 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Gestionnaire HAL 4 Sorbonne Université  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03703931

Submitted on : Tuesday, August 30, 2022-1:26:50 PM

Last modification on : Friday, March 1, 2024-3:32:02 PM

Download

Dates and versions

hal-03703931 , version 1 (30-08-2022)

Identifiers

Cite

S Gallien, M Massetti, P Flandre, H Leleu, D Descamps, et al.. Comparison of 48-Week Efficacies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimens: A Systematic Review and Network Meta-Analysis. HIV medicine, 2018, 19 (8), pp.559--571. ⟨10.1111/hiv.12643⟩. ⟨hal-03703931⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-PARIS7 UPEC IPLESP USPC SORBONNE-UNIVERSITE SU-MEDECINE
28 View
29 Download

Altmetric

Share

More